What if we could prevent people from developing obesity? The World Obesity Federation expects more than half the global population to develop overweight or obesity by 2035. However, treatment strategies such as lifestyle change, surgery and medications are not universally available or effective.
By drawing on genetic data from over five million people, an international team of researchers has created a genetic test called a polygenic risk score (PGS) that predicts adulthood obesity already in early childhood. This finding could help to identify children and adolescents at higher genetic risk of developing obesity, who could benefit from targeted preventative strategies, such as lifestyle interventions, at a younger age.
“What makes the score so powerful is its ability to predict, before the age of five, whether a child is likely to develop obesity in adulthood, well before other risk factors start to shape their weight later in childhood. Intervening at this point can have a huge impact,” says Assistant Professor Roelof Smit from the NNF Center for Basic Metabolic Research (CBMR) at the University of Copenhagen and lead author of the research published in Nature Medicine.
The study arises from the Genetic Investigation of Anthropometric Traits (GIANT) Consortium, an international collaboration of human genetics researchers dedicated to studying the genetic architecture of anthropometric traits such as human height and body mass index. The research involved a collaboration with the consumer genetics and research company 23andMe, inc., and the contributions of more than 600 scientists from 500 institutions, globally.
Twice as effective at predicting obesity as the next best test
The subtle variations in our genomes can greatly impact our health. Thousands of genetic variants have been identified that increase our risk of obesity, for example, variants that act in the brain and influence our appetite. A PGS is like a calculator that combines the effects of the different risk variants that a person carries and provides an overall score.
To create their PGS, the scientists drew on the genetic data of more than five million people – the largest and most diverse genetic dataset ever. They then tested their new PGS for obesity on datasets of the physical and genetic characteristics of more than 500,000 people. They found that their new PGS was twice as effective as the previous best test at predicting a person’s risk of developing obesity.
"This new polygenic score is a dramatic improvement in predictive power and a leap forward in the genetic prediction of obesity risk, which brings us much closer to clinically useful genetic testing," says Professor Ruth Loos from CBMR at the University of Copenhagen.
Genetics is not destiny
The scientists also investigated the relationship between a person’s genetic risk of obesity and the impact of lifestyle weight loss interventions, such as diet and exercise. They discovered that people with a higher genetic risk of obesity were more responsive to interventions but also regained weight more quickly when the interventions ended.
However, the new PGS has its limitations. Despite drawing on the genomes of a broader, more globally representative population, it was far better at predicting obesity in people with European-like ancestry than in people with African ancestry.
Link to the study: https://www.nature.com/articles/s41591-025-03827-z
Journal
Nature Medicine
Article Title
Polygenic prediction of body mass index and obesity through the life course and across ancestries
COI Statement
The views expressed in this article are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health. M.I.McC. (since June 2019) and A.Mah (since January 2020) are employees of Genentech and holders of Roche stock. Yu.J., Ji.S. and Ad.A. are employed by and hold stock or stock options in 23andMe, Inc. S.W.v.d.L. has received Roche funding for unrelated work. M.J.Ca. is Chief Scientist for Genomics England, a UK Government company. P.S. has received research awards from Pfizer, Inc. D.H. is currently employed at Bristol Myers Squibb. G.C.-P. is an employee of 23andMe, Inc. Since completing the work contributed to this paper, D.J.T. has left the University of Cambridge and is now employed by Genomics plc. I.N. is an employee and stock owner of Gilead Sciences; this work was conducted before employment by Gilead Sciences. P.Ki. received research support for basic, translational and clinical research projects from the German Research Foundation (DFG), the European Union, the British Heart Foundation, the Leducq Foundation, the Else-Kröner-Fresenius Foundation, the Dutch Heart Foundation (DHF), the Accelerating Clinical Trials funding stream in Canada, the Medical Research Council (UK) and the German Center for Cardiovascular Research and from several drug and device companies active in atrial fibrillation and has received honoraria from several such companies in the past but not in the last 5 years. P.Ki. is listed as inventor on two issued patents held by the University of Hamburg (Atrial Fibrillation Therapy WO 2015140571 and Markers for Atrial Fibrillation WO 2016012783). M.R. received consultancy fees from Bayer (OCEANIC-AF national PI) and InCarda Therapeutics (RESTORE-SR national PI) to the institution, unrelated to this research/dataset. M.J.Cu. has served on advisory boards or consulted for Boston Scientific, Biosense Webster, Janssen Scientific Affairs and Johnson & Johnson. R.J.F.L. has acted as a member of advisory boards and as a speaker for Eli Lilly and the Novo Nordisk Foundation, for which she has received fees. S.N. is a scientific advisor to Circle software, ADAS software, CardioSolv and ImriCor and receives grant support from Biosense Webster, ADAS software and ImriCor. S.A.Lu. is an employee of Novartis. S.A.Lu. received sponsored research support from Bristol Myers Squibb, Pfizer, Boehringer Ingelheim, Fitbit, Medtronic, Premier and IBM and has consulted for Bristol Myers Squibb, Pfizer, Blackstone Life Sciences and Invitae. P.T.E. receives sponsored research support from Bayer AG, Bristol Myers Squibb, Pfizer and Novo Nordisk; he has also served on advisory boards or consulted for Bayer AG. Her.S. has received honoraria for consulting from AstraZeneca, MSD/Merck, Daiichi, Servier, Amgen and Takeda Pharma. He has additionally received honoraria for lectures and/or chairs from AstraZeneca, BayerVital, BRAHMS, Daiichi, Medtronic, Novartis, Sanofi and Servier. S.E.G. is employed by Regeneron. C.J.W. is employed by Regeneron. B.M.P. serves on the Steering Committee of the Yale Open Data Access Project funded by Johnson & Johnson. K.S. is employed by deCODE Genetics/Amgen, Inc. Va.S. is employed by deCODE Genetics/ Amgen, Inc. G.T. is employed by deCODE Genetics/Amgen, Inc. U.T. is employed by deCODE Genetics/Amgen, Inc. E.Ba. is an employee of Empirico, Inc. Al.K. declares having received research grants through his affiliation from Novo Nordisk and Pharmaserve Lilly and consulting honoraria from Pharmaserve Lilly, Sanofi-Aventis, Novo Nordisk, MSD, AstraZeneca, ELPEN Pharma, Boehringer Ingelheim, Galenica Pharma, Epsilon Health and Winmedica. J.N.H. holds equity in Camp4 Therapeutics. A.E.L. is currently employed by and holds stock in Regeneron Pharmaceuticals, Inc. G.R.A. is an employee of Regeneron Pharmaceuticals and owns stock and stock options in Regeneron Pharmaceuticals. A.Pa. is currently employed by and holds stock in Regeneron Pharmaceuticals. O.G. is an employee and stock owner of UCB Pharma; this work was conducted before employment by UCB. N.G. is currently employed at Novo Nordisk A/S. M.E.K. is employed by SYNLAB Holding Deutschland GmbH. W.M. reports grants and personal fees from AMGEN, BASF, Sanofi, Siemens Diagnostics, Aegerion Pharmaceuticals, AstraZeneca, Danone Research, Numares, Pfizer and Hoffmann-La Roche; personal fees from MSD and Alexion; and grants from Abbott Diagnostics, all outside the submitted work. W.M. is employed by Synlab Holding Deutschland GmbH. C.J.O. is a current employee of Novartis Biomedical Research. S.M.D. receives research support from RenalytixAI and in-kind research support from Novo Nordisk, outside the scope of the current research. Ca.S. is currently employed by and holds stock in Regeneron Pharmaceuticals. J.C.F. received speaking honoraria from AstraZeneca, Merck and Novo Nordisk for talks over which he had full control of content and a consulting honorarium from AstraZeneca. H.L.L. receives support from a consulting contract between Data Tecnica International and the National Institute on Aging (NIA), National Institutes of Health (NIH). M.A.N. receives support from a consulting contract between Data Tecnica and the NIA, NIH. T.D.S. is a co-founder and shareholder of ZOE, Ltd. P.R.H.J.T. is a salaried employee of BioAge Labs, Inc. A.I.d.H. is currently an employee of AbbVie. The remaining authors declare no competing interests.